Jenscare’s Lux-Valve Plus Approved in Hong Kong-Macao Medicine and Equipment Connect

October 13, 2025—Jenscare Scientific Co., Ltd. announced that the Lux-Valve Plus transjugular tricuspid valve replacement system has been approved to be included in the Medical Device Catalog of Hong Kong-Macao Medicine and Equipment Connect. The device is a product of Jenscare Scientific (Netherlands) BV, a subsidiary of the company.

Jenscare noted that Hong Kong-Macao Medicine and Equipment Connect is a medical innovation policy implemented in the Guangdong-Hong Kong-Macao Greater Bay Area of China that allows medicines or medical devices that have been purchased and used by public hospitals in Hong Kong and Macao and are urgently needed, enabling commercial clinical application in designated medical institutions in the mainland of the Greater Bay Area after approval.

According to the company, Lux-Valve Plus is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation (TR) and high surgical risk. The Lux-Valve Plus is expected to initially be used in the region for the treatment of TR, noted the company. Approval for this access pathway was supported by the device’s clinical application experience, clinical performance, and product design in major countries/regions worldwide.

Lux-Valve Plus features ventricular-septum anchoring and a self-adaptive antileak ring and is delivered via a transjugular approach. It is available in seven sizes from 40 to 70 mm, stated Jenscare.